SynthesisMovement disorders clinical practice2025
Management of Anxiety in Parkinson's Disease.
Synthesis in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward.NeuroSci · 2026Review
- Meditation and breathwork on anxiety in Parkinson's disease: A pilot randomized controlled trial.Journal of Parkinson's disease · 2026Article
- Non-pharmacological interventions for anxiety and depression in Parkinson's disease.The Cochrane database of systematic reviews · 2026Article
- A Sensorimotor Framework for the Neurorehabilitation of Oculomotor Dysfunction in Parkinson's Disease.Journal of clinical medicine · 2026Review
- Parkinson's disease beyond motor symptoms: a review of the validity and limitations of current classification of non-motor symptoms.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnxiety is a common, distressing, hard-to-diagnose and hard-to-treat symptom in Parkinson's disease. No formal guidelines exist to assist management.
objectiveWe provide a pragmatic guide to detecting and managing anxiety in Parkinson's disease.
methodsIn this educational review, we describe the phenomenology, diagnostic challenges, hypothesized neurobiology, and the rationale for treatments for anxiety in Parkinson's disease. We review the major drug-classes and non-pharmacological treatment approaches in current use. We also present a meta-analysis of pharmacological treatments of anxiety derived from previously published systematic reviews of RCTs for depression in Parkinson's disease in which anxiety was a secondary outcome.
resultsIn our meta-analysis, anxiolytic medications showed a moderate overall anxiolytic effect compared to placebo (standardized mean difference: -0.45 [95% CI: -0.78, -0.12], p = 0.02). There were significant limitations with the studies included in this meta-analysis, with studies generally having small cohort sizes, and each specific pharmacotherapy was not studied in more than one randomized control trial. We also describe a pragmatic algorithm for individualized pharmacological management, based on our own experience of selecting treatments to optimize side-effect profile and treatment of comorbid symptoms.
conclusionsDetecting and treating anxiety likely benefits people with Parkinson's disease, though the current evidence-base for specific treatments or specific pharmacotherapy remains limited. Further work is needed to investigate the different evidence-based approaches for managing anxiety in Parkinson's disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.